The primary objective of the double-blind phase of the study is to compare the effects of two
doses of oxybutynin gel to placebo gel. The objective of the open-label extension is to
evaluate the extended safety and skin-irritation profile of topically administered oxybutynin
The hypothesis is that topically administered oxybutynin gel will decrease (compared to
placebo) the number of incontinence episodes per week, average daily urinary frequency, and
urinary urgency; increase average urinary void volume; and improve patient quality of life.